IKT

Inhibikase Therapeutics Inc.

Price

$2.44

return (12m)

43.53%

p/e

-6.94

p/bv

2.74

DIVIDEND YIELD

0.00%

IKT price

Inhibikase Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment IKT

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

8.93%

3 months

40.23%

1 year

43.53%

2 years

90.63%

5 years

-79.77%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals IKT

Valuation

P/E

-6.94

Sector -4.38

Industry -4.38

P/BV

2.74

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-12.44

Sector -263.09

Industry -263.09

EV/EBIT

-12.44

Sector -702.90

Industry -702.90

P/EBITDA

-6.41

Sector -4.39

Industry -4.39

P/EBIT

-6.41

Sector -4.73

Industry -4.73

P/Total Assets

2.57

Sector 1.49

Industry 1.49

P/Net Current Assets

2.77

Sector -11.70

Industry -11.70

P/Working Capital

2.77

Sector -3.19

Industry -3.19

EPS

-0.35

Sector -2.14

Industry -2.14

BVPS

0.88

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-39.54%

Sector -65.14%

Industry -65.14%

ROA

-37.06%

Sector -65.53%

Industry -65.53%

ROIC

-2,893.11%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

15.82

Sector 2.90

Industry 2.90

Net Debt / EBITDA

7.55

Sector -6.07

Industry -6.07

Net Debt / EBIT

7.55

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.04

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.94

Sector 0.41

Industry 0.41

Liabilities/Assets

0.06

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

32.60%

Sector -

Industry -

Fundamentals IKT

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
IKT Inhibikase Therapeutics Inc.	$2.44	41.86%	0.00%	-6.94	2.74	-39.54%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

IKT Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Inhibikase Therapeutics

Inhibikase Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

16 years

Founded: 2010

2020

Time since IPO - 6 years

8

Employees

Inhibikase Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $420.88 million, with shareholders equity totaling $153.33 million.

The company employs approximately 8 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Inhibikase Therapeutics Inc. reported $- in revenue, generating net income of $-60.63 million.

Key financial metrics include a P/E ratio of -6.94, a price-to-book (P/B) ratio of 2.74, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker IKT.

Market cap

$420.88 million

Net worth

$153.33 million

$153,330,000.00

Assets

$163.59 million

$163,590,000.00

Total Shares Outstanding

175.00 million

175,000,000

Average Daily Trading Volume

$861.49 Thousand

$861,487.66

Sector

Health Care

Industry

Biotechnology

IKT

IKT revenue and profits

Financial Results IKT

DRAG THE FRAME TO SEE MORE DATA

IKT cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Inhibikase Therapeutics (IKT) today?

A cotação de Inhibikase Therapeutics (IKT) hoje está em US$ 2.44, com uma variação de 43.53% em relação ao último ano. A cotação de Inhibikase Therapeutics (IKT) iniciou o ano negociando na casa dos US$ 2.05 e hoje está em US$ 2.44. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Inhibikase Therapeutics (IKT) e dados de ações do Ibovespa e mercados internacionais.

Quando Inhibikase Therapeutics (IKT) paga dividendos?

Inhibikase Therapeutics (IKT) não distribuiu dividendos no último ano.

Is Inhibikase Therapeutics (IKT) a good investment?

Atualmente, Inhibikase Therapeutics (IKT) está cotada a US$ 2.44, com um P/L de -6.94, representando um desvio de -424% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 43.53 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 43.53%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Inhibikase Therapeutics (IKT) stock?

Investir em ações de Inhibikase Therapeutics (IKT) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Inhibikase Therapeutics (IKT) yield today?

A rentabilidade de Inhibikase Therapeutics (IKT) foi de 8.93% no último mês, 43.53% no último ano e -79.77% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Inhibikase Therapeutics (IKT) hoje, o investimento total seria de US$ 244.00, com base na cotação atual de US$ 2.44.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 350.21
Em 5 anos: US$ 49.36
Em 10 anos: US$ 244.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

IKT

Inhibikase Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment IKT

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING IKT WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Inhibikase Therapeutics

Inhibikase Therapeutics Inc.

United States

16 years

2020

8

PROFIT X PRICE IKT

Financial Results IKT

IKT cash flow

Asset, Revenue and Profit Growth - IKT

IKT balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions